 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Selpercatinib can be expected in RET fusion-positive solid tumors

Lancet Oncol: Selpercatinib can be expected in RET fusion-positive solid tumors

 Last Update: 2022-10-02
 Source: Internet
 Author: User

Tags

viibryd 10 mg

atp 4 43

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Selpercatinib is a first-line highly selective RET kinase inhibitor with CNS activity that has shown efficacy

The LIBRETTO-001 study was designed to assess the efficacy and safety

The study was an ongoing 1/2, single-group, open-label basket trial of cancer patients aged 18 years (or ≥ 12 years, with regulatory authority permission) who had progressed after previous treatment with RET variants or did not have satisfactory treatment options, and administered Selpercatinib orally, and in the phase 1 dose increment, patients received Selpercatinib 20 mg/day or 20-240 mg*2 times/day; The recommended dose for Phase 2 is 160 mg*2 times/day

Between December 4, 2017 and August 4, 2021, a total of 45 RET fusion-positive cancer patients

Among the 41 patients whose efficacy could be evaluated, the objective response rate was 43.

In summary, Selpercatinib showed clinically significant activity in patients with RET fusion-positive tumors, and its safety was consistent

Original Source:

Vivek Subbiah, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.